To order Seprafilm or for more information, call 1-800-261-1570 Instructions for Use (IFU)
OPEN MOBILE NAV
For US Healthcare Professionals Only

IMPORTANT SAFETY INFORMATION

Seprafilm Adhesion Barrier is contraindicated in patients with a history of hypersensitivity to Seprafilm and/or to any component of Seprafilm. Seprafilm Adhesion Barrier is contraindicated for use wrapped directly [...]
View Full Important Safety Information

For US Healthcare Professionals Only
To order Seprafilm or for more information, call 1-800-261-1570

Before the Risk of Adhesions MAY BECOME THE REALITY

Seprafilm significantly reduces the incidence, extent, and severity of adhesions following abdominopelvic surgery1,2

RISK OF ADHESIONS

Up to 93% of patients have been shown to develop adhesions following laparotomy.2

SEPRAFILM EFFICACY

In a pivotal trial, only 49% of Seprafilm patients developed adhesions versus 94% of untreated patients.2*

*Randomized, double-blinded, multicenter, clinical study involving 183 patients (175 evaluable) with ulcerative colitis and familial polyposis undergoing abdominal surgery.

References

  1. Seprafilm® Adhesion Barrier Instructions for Use (IFU); Genzyme Corporation, Cambridge, MA; 2017.
  2. Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183(4):297-306.
©2002 - 2017 sanofi-aventis U.S. LLC, A SANOFI COMPANY
Legal Disclaimer   |   Privacy Policy